From Science to Sustainability: Why CGT Innovation Needs a Financial Strategy
Uncover the three most common pitfalls CGT companies face—and how to avoid them.
Breakthroughs don’t guarantee stability.
For cell and gene therapy (CGT) companies, scientific promise must be matched with financial and operational discipline. In today’s volatile market, leaders can’t afford to treat commercialization as an afterthought.
This article distills urgent lessons for CGT leaders who want to move beyond breakthroughs—and build for long-term success.
What’s inside:
- Real-world case studies of CGT companies that stumbled—despite strong science
- Red flags that weaken investor confidence and trigger funding loss
- The high cost of poor pipeline prioritization
- Why traditional M&A exit strategies no longer ensure safe landings
Download now to learn how execution, timing and narrative are shaping the next generation of CGT winners.
Related Content
Looking for exclusive insight?
